We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Flexion Therapeutics, Inc. (NASDAQ: FLXN) (“Flexion Therapeutics” or the “Company”) with Pacira BioSciences, Inc. (“Pacira”). Upon the closing of the transaction, Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right worth up to $8.00 per share in cash.
The Flexion Therapeutics merger investigation concerns whether the Board of Flexion Therapeutics has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.